Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for UTI Mutual Fund & PACs Suven Pharmaceuticals Ltd - 543064 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Company has received intimation from the RTA (Registrar & Share Transfer Agent) i.e. Kfin Technologies Limited regarding loss of share certificate(s), details are as per letter attached below. Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Friday, May 26, 2023 at 12:00 Noon IST to discuss the Audited Financial Results for the Q4 & FY23, to be declared on May 25, 2023. This is for your information and record. Suven Pharmaceuticals Ltd - 543064 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Thursday, The 25Th May, 2023
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2023 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Thursday, the 25th May, 2023 at 11:30 a.m. at the Registered Office, SDE Serene Chambers, 3rd Floor, Road No 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider, inter alia, and approve the following matter(s): To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ended March 31, 2023 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st April, 2023 as per PIT Code of the Company. Trading window will be opened from 29th May, 2023. You are requested to take this notice on your record.
CCI clears Berhyanda's 76% stake acquisition in Suven Pharmaceuticals
The Competition Commission of India (CCI) on Thursday said it has cleared Berhyanda Ltd's acquisition of a 76.10 per cent stake in pharmaceutical firm Suven Pharmaceuticals Ltd. Berhyanda Ltd is a wholly-owned subsidiary of Berhyanda Midco Ltd, which is an affiliate of Advent International Corporation. The proposed combination relates to the acquisition by Berhyanda Ltd for up to 76.10 per cent of the voting share capital of Suven Pharmaceuticals Ltd, by way of a share purchase agreement dated December 26, 2022, and pursuant to the mandatory open offer in compliance with Sebi's SAST (Substantial Acquisition of Shares and Takeovers) regulations, according to an official release. Suven Pharmaceuticals Ltd is a biopharmaceutical company that offers its services to global pharmaceutical and agrochemical majors. Deals beyond a certain threshold require approval from the regulator, which keeps a tab on unfair business practices in the marketplace. Suven Pharmaceuticals Ltd - 543064 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySuven Pharmaceuticals Ltd 2CIN NO.L24299TG2018PLC128171 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 24.56 4Highest Credit Rating during the previous FY A+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: K HANUMANTHA RAO Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: [email protected] Name of the Chief Financial Officer: P Subba Rao Designation: Chief FInancial Officer EmailId: [email protected] Date: 18/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Suven Pharmaceuticals Ltd - 543064 - Submission Of Compliance Certificate Under Regulation 40(10) For The Year Ended 31St March, 2023
With reference to above subject, please find enclosed Compliance Certificate for the year ended 31st March, 2023 issued by the Practicing Company Secretary, under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We request you to take this document on your record. Suven Pharmaceuticals Ltd - 543064 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018, please find enclosed herewith the Confirmation Certificates issued by KFin Technologies Limited, Registrar and Share Transfer Agents of the Company, for the quarter ended March 31, 2023. This is for your information and record. Suven Pharmaceuticals Ltd - 543064 - Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Year Ended 31St March, 2023
With reference to the above subject, please find enclosed compliance certificate for the year ended 31st March, 2023 duly signed by the Compliance Officer and authorised representative of the Share Transfer Agent (KFin Technologies Limited, Hyderabad), under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We request you to take this document on your record.